BR112016023668A2 - hiperestimulação ovariana controlada com hormônio de estimulação de folículo humano recombinante aperfeiçoado - Google Patents
hiperestimulação ovariana controlada com hormônio de estimulação de folículo humano recombinante aperfeiçoadoInfo
- Publication number
- BR112016023668A2 BR112016023668A2 BR112016023668A BR112016023668A BR112016023668A2 BR 112016023668 A2 BR112016023668 A2 BR 112016023668A2 BR 112016023668 A BR112016023668 A BR 112016023668A BR 112016023668 A BR112016023668 A BR 112016023668A BR 112016023668 A2 BR112016023668 A2 BR 112016023668A2
- Authority
- BR
- Brazil
- Prior art keywords
- recombinant human
- controlled
- ovarian hyperstimulation
- human follicle
- improved recombinant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/42—Gynaecological or obstetrical instruments or methods
- A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
- A61B17/43—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for artificial insemination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Surgery (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medical Informatics (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
a presente invenção refere-se a métodos para a hiperestimulação ovariana controlada em um indivíduo feminino usando-se hormônio de estimulação de folículo humano recombinante aperfeiçoado (rhfsh). os métodos resultam em um alto número de ovócitos fertilizáveis mesmo em baixas quantidades de fsh administradas ao indivíduo feminino.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461981621P | 2014-04-18 | 2014-04-18 | |
PCT/EP2015/058352 WO2015158875A1 (en) | 2014-04-18 | 2015-04-17 | Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016023668A2 true BR112016023668A2 (pt) | 2017-10-17 |
Family
ID=53015773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016023668A BR112016023668A2 (pt) | 2014-04-18 | 2015-04-17 | hiperestimulação ovariana controlada com hormônio de estimulação de folículo humano recombinante aperfeiçoado |
Country Status (13)
Country | Link |
---|---|
US (1) | US20170035854A1 (pt) |
EP (1) | EP3131571A1 (pt) |
JP (1) | JP2017513853A (pt) |
KR (1) | KR20160144480A (pt) |
CN (1) | CN106413735A (pt) |
AR (1) | AR100132A1 (pt) |
AU (1) | AU2015248793A1 (pt) |
BR (1) | BR112016023668A2 (pt) |
CA (1) | CA2945883A1 (pt) |
IL (1) | IL248362A0 (pt) |
MX (1) | MX2016013449A (pt) |
SG (1) | SG11201608132UA (pt) |
WO (1) | WO2015158875A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
US11389133B2 (en) | 2016-10-28 | 2022-07-19 | Samsung Electronics Co., Ltd. | Method and apparatus for follicular quantification in 3D ultrasound images |
BR112020003379A2 (pt) * | 2017-09-01 | 2020-08-25 | Ferring B.V. | usos de hormônio folículo-estimulante recombinante (fsh) para estimulação ovariana controlada |
CN110570952B (zh) * | 2018-06-05 | 2022-04-12 | 北京大学第三医院 | 预测拮抗剂方案下受试者卵巢低反应概率的***及指导***起始用药剂量选择的*** |
CN112603990B (zh) * | 2020-12-17 | 2022-03-08 | 广州医药研究总院有限公司 | 提高犬卵巢卵丘-***复合体数量的试剂盒及其应用 |
CN116798634B (zh) * | 2023-08-25 | 2023-11-21 | 北京大学深圳医院 | 一种fsh启动剂量预测***、电子设备及存储介质 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2464368A1 (en) | 2001-10-22 | 2003-05-01 | Applied Research Systems Ars Holding N.V. | Compositions of fsh with high sialylation degree and their use for the preparation of medicaments |
WO2011035884A1 (en) * | 2009-09-22 | 2011-03-31 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
EP2325194A1 (en) | 2009-11-24 | 2011-05-25 | Glycotope GmbH | Process for the purification of glycoproteins |
WO2012016576A1 (en) * | 2010-08-04 | 2012-02-09 | Glycotope Gmbh | Improved recombinant human follicle-stimulating hormone |
-
2015
- 2015-04-17 SG SG11201608132UA patent/SG11201608132UA/en unknown
- 2015-04-17 KR KR1020167031711A patent/KR20160144480A/ko unknown
- 2015-04-17 AU AU2015248793A patent/AU2015248793A1/en not_active Abandoned
- 2015-04-17 WO PCT/EP2015/058352 patent/WO2015158875A1/en active Application Filing
- 2015-04-17 BR BR112016023668A patent/BR112016023668A2/pt not_active Application Discontinuation
- 2015-04-17 MX MX2016013449A patent/MX2016013449A/es unknown
- 2015-04-17 AR ARP150101170A patent/AR100132A1/es unknown
- 2015-04-17 CA CA2945883A patent/CA2945883A1/en not_active Abandoned
- 2015-04-17 EP EP15719165.1A patent/EP3131571A1/en not_active Withdrawn
- 2015-04-17 US US15/303,703 patent/US20170035854A1/en not_active Abandoned
- 2015-04-17 JP JP2016562890A patent/JP2017513853A/ja active Pending
- 2015-04-17 CN CN201580020167.7A patent/CN106413735A/zh active Pending
-
2016
- 2016-10-13 IL IL248362A patent/IL248362A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2016013449A (es) | 2017-05-04 |
AU2015248793A1 (en) | 2016-11-03 |
AR100132A1 (es) | 2016-09-14 |
WO2015158875A1 (en) | 2015-10-22 |
SG11201608132UA (en) | 2016-11-29 |
KR20160144480A (ko) | 2016-12-16 |
IL248362A0 (en) | 2016-11-30 |
JP2017513853A (ja) | 2017-06-01 |
EP3131571A1 (en) | 2017-02-22 |
CA2945883A1 (en) | 2015-10-22 |
CN106413735A (zh) | 2017-02-15 |
US20170035854A1 (en) | 2017-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016023668A2 (pt) | hiperestimulação ovariana controlada com hormônio de estimulação de folículo humano recombinante aperfeiçoado | |
ZA201802657B (en) | Crystal forms of beta-nicotinamide mononucleotide | |
GT201700072A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
MX2022004374A (es) | Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer. | |
UY35548A (es) | Péptidos terapéuticos para el tratamiento de trastornos metabólicos. | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
BR112017023233A2 (pt) | métodos para tratamento de câncer | |
BR112015021371A2 (pt) | uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares | |
BR112017009584A2 (pt) | tratamento de retinite pigmentosa com n-acetilcisteína amida | |
BR112016022742A2 (pt) | composições e métodos para modular a expressão de receptor de hormônio do crescimento | |
BR112017005202A2 (pt) | anticorpos anti-met e composições | |
EP3148569A4 (en) | Therapeutic tratment of skin disease with recombinant commensal skin microorganisms | |
BR112015033069A2 (pt) | moduladores de receptor do hormônio de crescimento | |
BR112017002809A2 (pt) | métodos para tratar câncer cervical | |
HK1243430A1 (zh) | 通過施用il-6r拮抗劑治療乾眼病的方法 | |
BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
EP4275746A3 (en) | Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use | |
EP3368059A4 (en) | TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) -1 ANALOGUE | |
AR100944A1 (es) | ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w | |
BR112018010155A2 (pt) | segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca | |
BR112017004739A2 (pt) | ligantes de hormônio folículo estimulante, complexo de ligante e gonadotrofina, uso de um ligante, e composição farmacêutica | |
BR112015028737A2 (pt) | métodos para a produção e/ou purificação de hormônios | |
MX2015013091A (es) | Metodos mejorados de uso para secretoglobinas humanas recombinantes. | |
BR112016023450A2 (pt) | uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce | |
BR112018003779A2 (pt) | sialil-di-lewis a conforme expresso em glicoproteínas, mas não glicolipídios, como um alvo de câncer funcional e anticorpos para o mesmo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |